Compare Abbott Laboratories (ABT) vs ASE Technology Holding Co Ltd (ASX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs ASE Technology Holding Co Ltd — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while ASE Technology Holding Co Ltd trades at $40.27 (market cap $89.31B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | ASX | |
|---|---|---|
Market Cap | $166.94B | $89.31B |
Sector | Health | Technology |
52-Week High | $136.62 | $45.12 |
52-Week Low | $82.57 | $9.50 |
Enterprise Value | $193.69B | $93.75B |
Dividend Yield | 2.63% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ASE Technology Holding (ASX) trades at $39.65, down 5.3% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong quarterly earnings beats, with Q1 2026 EPS of $0.20 beating expectations of $0.1703. Revenue grew to $645.39B in 2025, with net income of $40.02B, while valuation ratios like P/E of 67.98 and P/B of 8.67 suggest premium pricing. Recent news highlights AI-driven demand boosting its LEAP advanced packaging business, with 2026 revenue projected above $3.5B.
Outlook remains positive due to AI infrastructure growth and margin expansion, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is 80% buy, with institutional sentiment buoyed by earnings momentum, though the stock's recent decline may reflect profit-taking after a 77.1% three-month surge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →
